Chinese General Practice ›› 2023, Vol. 26 ›› Issue (08): 911-916.DOI: 10.12114/j.issn.1007-9572.2022.0660
• Original Research • Previous Articles Next Articles
Received:
2022-09-11
Revised:
2022-11-10
Published:
2023-03-15
Online:
2022-11-24
Contact:
DENG Xia, YUAN Guoyue
通讯作者:
邓霞, 袁国跃
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0660
组别 | 例数 | 性别(男/女) | 年龄(岁) | T2DM病程〔M(P25,P75),月〕 | 高血压病史〔n(%)〕 | 吸烟史〔n(%)〕 | 饮酒史〔n(%)〕 | BMI(kg/m2) | WHR〔M(P25,P75)〕 |
---|---|---|---|---|---|---|---|---|---|
非NAFLD组 | 50 | 27/23 | 58.8±12.7 | 120(33,168) | 21(42.0) | 12(24.0) | 9(18.0) | 23.8±3.0 | 0.93(0.88,0.97) |
NAFLD组 | 80 | 47/33 | 53.6±11.8 | 24(1,120) | 35(43.8) | 22(27.5) | 12(15.0) | 25.8±2.9 | 0.94(0.91,0.98) |
检验统计量值 | 0.283b | 2.359 | -3.545a | 0.038b | 0.195b | 0.204b | -3.884 | -1.077a | |
P值 | 0.595 | 0.020 | <0.001 | 0.845 | 0.659 | 0.651 | <0.001 | 0.282 | |
组别 | SBP(mm Hg) | DBP〔M(P25,P75),mm Hg〕 | FPG(mmol/L) | 2 hPG(mmol/L) | FIns〔M(P25,P75),U/ml〕 | 2 hIns〔M(P25,P75),U/ml〕 | FCP(g/L) | 2 hCP〔M(P25,P75),g/L〕 | |
非NAFLD组 | 134±17 | 80(73,86) | 9.94±3.55 | 19.65±5.50 | 4.84(3.17,11.89) | 23.43(13.76,46.83) | 1.93±0.96 | 3.42(2.53,5.31) | |
NAFLD组 | 134±17 | 80(72,90) | 10.26±3.03 | 18.90±4.63 | 8.35(5.18,13.33) | 30.00(17.81,52.99) | 2.66±1.12 | 5.35(3.50,7.63) | |
检验统计量值 | 0.089 | -0.062a | -0.540 | 0.837 | -2.508a | -2.070a | -3.811 | -3.718a | |
P值 | 0.929 | 0.950 | 0.590 | 0.404 | 0.012 | 0.038 | <0.001 | <0.001 | |
组别 | HOMA-IR〔M(P25,P75)〕 | HOMA-β〔M(P25,P75)〕 | HbA1c(%) | TG〔M(P25,P75),mmol/L〕 | TC〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C(mmol/L) | ||
非NAFLD组 | 2.47(1.58,4.21) | 17.22(8.26,49.21) | 9.62±2.13 | 1.56(1.12,2.12) | 4.64(4.23,5.55) | 1.09(0.93,1.31) | 2.85±0.80 | ||
NAFLD组 | 3.64(2.56,4.98) | 26.86(14.98,45.50) | 9.50±2.03 | 2.24(1.51,3.72) | 4.83(4.14,6.01) | 1.06(0.87,1.23) | 2.91±0.84 | ||
检验统计量值 | -2.852a | -1.847a | 0.316 | -3.759a | -0.658a | -1.146a | -0.416 | ||
P值 | 0.004 | 0.065 | 0.929 | <0.010 | 0.511 | 0.252 | 0.678 | ||
组别 | ALT〔M(P25,P75),U/L〕 | AST〔M(P25,P75),U/L〕 | SUA(μmol/L) | Scr〔M(P25,P75),mol/L〕 | BUN〔M(P25,P75),mmol/L〕 | EDA〔M(P25,P75),ng/L〕 | |||
非NAFLD组 | 15.10(10.03,22.00) | 14.30(12.10,19.65) | 273.07±89.84 | 58.10(50.00,72.98) | 5.50(4.49,6.62) | 309.13(235.39,402.56) | |||
NAFLD组 | 27.45(14.30,43.43) | 19.75(13.50,29.10) | 314.05±88.76 | 58.60(51.25,68.65) | 4.95(4.28,5.72) | 363.17(312.50,437.17) | |||
检验统计量值 | -3.963a | -2.759a | -2.549 | -0.502a | -2.393a | -2.859a | |||
P值 | <0.010 | 0.006 | 0.012 | 0.615 | 0.017 | 0.004 |
Table 1 Comparison of baseline data between T2DM patients with and without ultrasound-detected NAFLD
组别 | 例数 | 性别(男/女) | 年龄(岁) | T2DM病程〔M(P25,P75),月〕 | 高血压病史〔n(%)〕 | 吸烟史〔n(%)〕 | 饮酒史〔n(%)〕 | BMI(kg/m2) | WHR〔M(P25,P75)〕 |
---|---|---|---|---|---|---|---|---|---|
非NAFLD组 | 50 | 27/23 | 58.8±12.7 | 120(33,168) | 21(42.0) | 12(24.0) | 9(18.0) | 23.8±3.0 | 0.93(0.88,0.97) |
NAFLD组 | 80 | 47/33 | 53.6±11.8 | 24(1,120) | 35(43.8) | 22(27.5) | 12(15.0) | 25.8±2.9 | 0.94(0.91,0.98) |
检验统计量值 | 0.283b | 2.359 | -3.545a | 0.038b | 0.195b | 0.204b | -3.884 | -1.077a | |
P值 | 0.595 | 0.020 | <0.001 | 0.845 | 0.659 | 0.651 | <0.001 | 0.282 | |
组别 | SBP(mm Hg) | DBP〔M(P25,P75),mm Hg〕 | FPG(mmol/L) | 2 hPG(mmol/L) | FIns〔M(P25,P75),U/ml〕 | 2 hIns〔M(P25,P75),U/ml〕 | FCP(g/L) | 2 hCP〔M(P25,P75),g/L〕 | |
非NAFLD组 | 134±17 | 80(73,86) | 9.94±3.55 | 19.65±5.50 | 4.84(3.17,11.89) | 23.43(13.76,46.83) | 1.93±0.96 | 3.42(2.53,5.31) | |
NAFLD组 | 134±17 | 80(72,90) | 10.26±3.03 | 18.90±4.63 | 8.35(5.18,13.33) | 30.00(17.81,52.99) | 2.66±1.12 | 5.35(3.50,7.63) | |
检验统计量值 | 0.089 | -0.062a | -0.540 | 0.837 | -2.508a | -2.070a | -3.811 | -3.718a | |
P值 | 0.929 | 0.950 | 0.590 | 0.404 | 0.012 | 0.038 | <0.001 | <0.001 | |
组别 | HOMA-IR〔M(P25,P75)〕 | HOMA-β〔M(P25,P75)〕 | HbA1c(%) | TG〔M(P25,P75),mmol/L〕 | TC〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C(mmol/L) | ||
非NAFLD组 | 2.47(1.58,4.21) | 17.22(8.26,49.21) | 9.62±2.13 | 1.56(1.12,2.12) | 4.64(4.23,5.55) | 1.09(0.93,1.31) | 2.85±0.80 | ||
NAFLD组 | 3.64(2.56,4.98) | 26.86(14.98,45.50) | 9.50±2.03 | 2.24(1.51,3.72) | 4.83(4.14,6.01) | 1.06(0.87,1.23) | 2.91±0.84 | ||
检验统计量值 | -2.852a | -1.847a | 0.316 | -3.759a | -0.658a | -1.146a | -0.416 | ||
P值 | 0.004 | 0.065 | 0.929 | <0.010 | 0.511 | 0.252 | 0.678 | ||
组别 | ALT〔M(P25,P75),U/L〕 | AST〔M(P25,P75),U/L〕 | SUA(μmol/L) | Scr〔M(P25,P75),mol/L〕 | BUN〔M(P25,P75),mmol/L〕 | EDA〔M(P25,P75),ng/L〕 | |||
非NAFLD组 | 15.10(10.03,22.00) | 14.30(12.10,19.65) | 273.07±89.84 | 58.10(50.00,72.98) | 5.50(4.49,6.62) | 309.13(235.39,402.56) | |||
NAFLD组 | 27.45(14.30,43.43) | 19.75(13.50,29.10) | 314.05±88.76 | 58.60(51.25,68.65) | 4.95(4.28,5.72) | 363.17(312.50,437.17) | |||
检验统计量值 | -3.963a | -2.759a | -2.549 | -0.502a | -2.393a | -2.859a | |||
P值 | <0.010 | 0.006 | 0.012 | 0.615 | 0.017 | 0.004 |
指标 | 年龄 | BMI | WHR | SBP | DBP | FPG | 2 hPG | FIns | 2 hIns | FCP | 2 hCP | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
r(rs)值 | 0.222 | 0.093 | -0.113a | 0.094 | -0.020a | -0.104 | 0.040 | 0.224a | 0.207a | 0.069 | 0.149a | |
P值 | 0.011 | 0.291 | 0.199 | 0.286 | 0.823 | 0.239 | 0.653 | 0.010 | 0.018 | 0.439 | 0.091 | |
指标 | HOMA-IR | HOMA-β | HbA1c | TG | TC | HDL-C | LDL-C | ALT | AST | SUA | Scr | BUN |
r(rs)值 | 0.210a | 0.173a | 0.017 | 0.038a | 0.116a | 0.089a | 0.089 | 0.158a | 0.251a | 0.103 | 0.187a | 0.029a |
P值 | 0.017 | 0.049 | 0.844 | 0.669 | 0.188 | 0.315 | 0.316 | 0.072 | 0.004 | 0.244 | 0.033 | 0.747 |
Table 2 Correlation analysis of serum ectodysplasin A with clinical and biochemical indices in T2DM patients
指标 | 年龄 | BMI | WHR | SBP | DBP | FPG | 2 hPG | FIns | 2 hIns | FCP | 2 hCP | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
r(rs)值 | 0.222 | 0.093 | -0.113a | 0.094 | -0.020a | -0.104 | 0.040 | 0.224a | 0.207a | 0.069 | 0.149a | |
P值 | 0.011 | 0.291 | 0.199 | 0.286 | 0.823 | 0.239 | 0.653 | 0.010 | 0.018 | 0.439 | 0.091 | |
指标 | HOMA-IR | HOMA-β | HbA1c | TG | TC | HDL-C | LDL-C | ALT | AST | SUA | Scr | BUN |
r(rs)值 | 0.210a | 0.173a | 0.017 | 0.038a | 0.116a | 0.089a | 0.089 | 0.158a | 0.251a | 0.103 | 0.187a | 0.029a |
P值 | 0.017 | 0.049 | 0.844 | 0.669 | 0.188 | 0.315 | 0.316 | 0.072 | 0.004 | 0.244 | 0.033 | 0.747 |
指标 | β | 95%CI | SE | 标准化β | t值 | P值 |
---|---|---|---|---|---|---|
常量 | 502.738 | (203.176,802.300) | 151.361 | — | 3.321 | 0.001 |
年龄 | 1.957 | (0.412,3.502) | 0.781 | 0.214 | 2.506 | 0.013 |
WHR | -328.845 | (-638.903,-18.788) | 156.664 | -0.175 | -2.099 | 0.038 |
2 hIns | 0.523 | (0.036,1.011) | 0.246 | 0.181 | 2.125 | 0.036 |
AST | 2.148 | (0.520,3.776) | 0.823 | 0.220 | 2.611 | 0.010 |
Table 3 Multiple linear regression analysis of factors associated with serum ectodysplasin A in T2DM
指标 | β | 95%CI | SE | 标准化β | t值 | P值 |
---|---|---|---|---|---|---|
常量 | 502.738 | (203.176,802.300) | 151.361 | — | 3.321 | 0.001 |
年龄 | 1.957 | (0.412,3.502) | 0.781 | 0.214 | 2.506 | 0.013 |
WHR | -328.845 | (-638.903,-18.788) | 156.664 | -0.175 | -2.099 | 0.038 |
2 hIns | 0.523 | (0.036,1.011) | 0.246 | 0.181 | 2.125 | 0.036 |
AST | 2.148 | (0.520,3.776) | 0.823 | 0.220 | 2.611 | 0.010 |
变量 | 赋值 |
---|---|
发生NAFLD | 是=1,否=0 |
EDA | 实测值 |
高血压病史 | 有=1,无=0 |
吸烟史 | 有=1,无=0 |
饮酒史 | 有=1,无=0 |
性别 | 男=1,女=2 |
年龄 | 实测值 |
T2DM病程 | 实测值 |
BMI | 实测值 |
WHR | 实测值 |
Table 4 Assignment for influencing factors of NAFLD in T2DM analyzed using multivariate Logistic regression
变量 | 赋值 |
---|---|
发生NAFLD | 是=1,否=0 |
EDA | 实测值 |
高血压病史 | 有=1,无=0 |
吸烟史 | 有=1,无=0 |
饮酒史 | 有=1,无=0 |
性别 | 男=1,女=2 |
年龄 | 实测值 |
T2DM病程 | 实测值 |
BMI | 实测值 |
WHR | 实测值 |
指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
未校正模型 | 0.004 | 0.002 | 5.421 | 0.020 | 1.004 | (1.001,1.008) |
模型1 | 0.005 | 0.002 | 7.436 | 0.006 | 1.005 | (1.001,1.009) |
模型2 | 0.006 | 0.002 | 7.074 | 0.008 | 1.006 | (1.001,1.010) |
模型3 | 0.006 | 0.002 | 7.249 | 0.007 | 1.006 | (1.002,1.010) |
Table 5 Multivariate Logistic regression analysis of factors affecting NAFLD in T2DM patients
指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
未校正模型 | 0.004 | 0.002 | 5.421 | 0.020 | 1.004 | (1.001,1.008) |
模型1 | 0.005 | 0.002 | 7.436 | 0.006 | 1.005 | (1.001,1.009) |
模型2 | 0.006 | 0.002 | 7.074 | 0.008 | 1.006 | (1.001,1.010) |
模型3 | 0.006 | 0.002 | 7.249 | 0.007 | 1.006 | (1.002,1.010) |
[1] |
|
[2] |
|
[3] |
|
[4] |
刘君,杨艳君,韩伟. 尿微量白蛋白与尿肌酐比值对2型糖尿病合并非酒精性脂肪肝的影响[J]. 安徽医药,2021,25(8):1656-1659.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care,2014,37(Suppl 1):S81-90. DOI:10.2337/dc14-s081.
|
[11] |
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订)[J]. 中华内科杂志,2010,49(3):275-278. DOI:10.3760/cma.j.issn.0578-1426.2010.03.029.
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
卢亚男,刘丽俊,李伟. GA/HbA1c比值与2型糖尿病合并非酒精性脂肪肝相关[J]. 基础医学与临床,2020,40(12):1636-1639. DOI:10.16352/j.issn.1001-6325.2020.12.006.
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[1] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[2] | TANG Can, LI Xiangyang, LI Jing, QIN Haoran, ZHU Hong. The Value of Nomogram Established by Serological Indicators and Tumor Diameter to Predict the Risk of Microvascular Invasion in Hepatocellular Carcinoma [J]. Chinese General Practice, 2023, 26(36): 4514-4520. |
[3] | LU Yihan, WANG Jiwen, SUN Yue, FENG Runrun, HAN Yufei, SONG Zhenzhen, SUN Ying, DAI Huihua, CHEN Xing. Risk Factors and Maternal and Neonatal Outcomes of Pregnant Women with Total Labor over 24 Hours [J]. Chinese General Practice, 2023, 26(35): 4459-4463. |
[4] | CHENG Hao, ZHOU Jinchi, LIU Xi, KANG Lin, FAN Ahui, DOU Weijia, LIU Zhenxiong. Risk Factors Analysis and Risk Prediction Model Establishment for Rebleeding Events within 3 Years after Endoscopic Treatment of Gastroesophageal Varices in Liver Cirrhosis Patients [J]. Chinese General Practice, 2023, 26(35): 4446-4452. |
[5] | LUO Weigang, YIN Yuanyuan, LIU Wanhu, XU Yuzhu, CAO Xiaoyun, BU Wei, ZHANG Lingyan, REN Huiling. Correlation of Triglyceride Glucose Index with Early Neurological Deterioration in Patients with Single Subcortical Infarction [J]. Chinese General Practice, 2023, 26(35): 4419-4424. |
[6] | LIU Weina, GE Haiyan, MA Jing, CAO Qinying, BAI Xingyu, CUI Shifang, QIAO Yanxia. A Study on the Relationship of Vitamin A and E Levels in Umbilical Cord Blood with Respiratory Distress Syndrome in Preterm Infants [J]. Chinese General Practice, 2023, 26(33): 4152-4158. |
[7] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, ZHANG Jin. The Correlation of Dietary Inflammatory Index with Overweight, Obesity and Abdominal Obesity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4089-4097. |
[8] | MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou. Interpretation of Report on Cardiovascular Health and Diseases in China 2022 [J]. Chinese General Practice, 2023, 26(32): 3975-3994. |
[9] | LI Yujing, JIN Yichao, CHEN Xing, JI Mengying, DAI Huihua. Risk Factors for Endometrial Lesions Detected by Hysteroscopy in Breast Cancer Patients Taking Tamoxifen [J]. Chinese General Practice, 2023, 26(32): 4026-4030. |
[10] | HU Jiayu, REN Lijue, JIN Huanhuan, SUN Tingting, JIN Meina, ZHOU Xueli, WEI Cuiying. The Level of Adipokine Metrnl and Its Relationship with Inflammation and Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome [J]. Chinese General Practice, 2023, 26(30): 3748-3752. |
[11] | ZHOU Xiaoqi, LIU Xinhui, ZHANG Wei, LI Changfeng, YAN Yaqiong. Association of Alanine Transaminase and Aspartate Aminotransferase/Alanine Transaminase Ratio with Type 2 Diabetes and Metabolic Syndrome in the Elderly [J]. Chinese General Practice, 2023, 26(29): 3645-3649. |
[12] | HUANG He, ZOU Zhizhuo, LI Qin, LIU Dong, WANG Yuqi, TAN Rongshao. Association between Calf Circumference and Sarcopenia in Kidney Transplant Recipients [J]. Chinese General Practice, 2023, 26(27): 3403-3410. |
[13] | BAI Yitong, LIN Lianjie, PEI Dongmei. Correlation between the Severity of Metabolic-associated Fatty Liver Disease and Thyroid Nodules [J]. Chinese General Practice, 2023, 26(27): 3392-3396. |
[14] | KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258. |
[15] | REN Yuanyuan, CHENG Gong, JIANG Hongying, WANG Yiyang, CHEN Liang, ZHAO Hui, LIANG Chenyuan. Analysis of Influencing Factors of Coronary Artery Calcification and Its Severity in Patients with Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(24): 2980-2985. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||